financetom
Business
financetom
/
Business
/
Propel Completes Acquisition of QuidMarket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Propel Completes Acquisition of QuidMarket
Nov 15, 2024 11:05 AM

10:22 AM EST, 11/15/2024 (MT Newswires) -- Propel Holdings ( PRLPF ) on Friday said it has completed acquisition of Stagemount (dba QuidMarket), a UK-based fintech lender specializing in credit for underserved consumers. The final purchase price was US$71 million, excluding closing adjustments, and was paid in cash.

"The closing of the acquisition of QuidMarket is a critical step in our journey to become a global leader in building financial opportunity. A leading UK fintech lender, QuidMarket is focused on the 20 million underserved consumers in the UK. Backed by Propel's AI-powered technology, financial and operational expertise, and capital resources, we believe QuidMarket will be able to accelerate its growth while broadening access to credit for more underserved consumers," said Clive Kinross, CEO of Propel.

The acquisition will be immediately accretive, on a pro forma adjusted basis, and excluding transaction costs and before any synergies.

The purchase price for the acquisition was funded from the proceeds of Propel's C$115 million bought deal offering of subscription receipts, which closed on Oct. 3.

With the acquisition closed, each holder of a subscription receipt will receive one common share of Propel and a C$0.15 dividend per share payable on Dec. 4.

Propel was at last look down $0.42 or 1% to $35.29, on the Toronto Stock Exchange.

Price: 35.30, Change: -0.26, Percent Change: -0.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis Gets FDA Accelerated Approval for Vanrafia
Novartis Gets FDA Accelerated Approval for Vanrafia
Apr 3, 2025
04:41 AM EDT, 04/03/2025 (MT Newswires) -- Novartis ( NVS ) said late Wednesday the US Food and Drug Administration granted accelerated approval for Vanrafia to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression. IgAN is a progressive, rare kidney disease. Data from an ongoing phase III showed that Vanrafia achieved...
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Apr 3, 2025
04:35 AM EDT, 04/03/2025 (MT Newswires) -- The slate of tariffs from the Trump administration is worse than the worst case scenario feared by analysts, according to Wedbush Securities. In a note emailed to clients on Wednesday, Wedbush analysts, led by Daniel Ives, said tech stocks will be under major pressure following the announcement. On Wednesday, the Trump administration unveiled...
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Apr 3, 2025
By Rajasik Mukherjee (Reuters) - Shares of Australia's consumer staple companies rose on Thursday, driven by grocers Coles and Woolworths, as investors moved to safer bets after U.S. President Donald Trump's reciprocal tariffs sparked global market turmoil. Shares of the sector ended 1.3% higher while the broader Australian market fell 0.9% to its lowest since March 14. Coles rose 2.1%...
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Apr 3, 2025
04:23 AM EDT, 04/03/2025 (MT Newswires) -- Mesoblast (MESO) said late Wednesday it expets to have a type B meeting with the US Food and Drug Administration during the current quarter to discuss the accelerated approval pathway for ischemic heart failure treatment candidate, Revascor. The main goals of the meeting are to get FDA feedback on relevant chemistry, manufacturing &...
Copyright 2023-2025 - www.financetom.com All Rights Reserved